315 related articles for article (PubMed ID: 8631017)
21. Disposition and metabolism of the new hypocholesterolemic compound S-8921 in rats and dogs.
Yamaguchi T; Nakajima Y; Mizobuchi M; Inazawa K; Kanazu T; Kadono K; Ohkawa T; Iwatani K
Arzneimittelforschung; 1998 Oct; 48(10):995-1006. PubMed ID: 9825117
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of the new thyrotropin releasing hormone analogue montirelin hydrate. 1st communication: plasma concentrations, metabolism and excretion after a single intravenous administration to rats, dogs and monkeys.
Sugimoto T; Hayashi T; Okita A; Morino A
Arzneimittelforschung; 1996 Feb; 46(2):106-13. PubMed ID: 8720298
[TBL] [Abstract][Full Text] [Related]
23. Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity.
Hornung RL; Pearson JW; Beckwith M; Longo DL
Cancer Res; 1992 Jan; 52(1):101-7. PubMed ID: 1727368
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics and tissue disposition of a chimeric oligodeoxynucleoside phosphorothioate in rats after intravenous administration.
Zhang R; Iyer RP; Yu D; Tan W; Zhang X; Lu Z; Zhao H; Agrawal S
J Pharmacol Exp Ther; 1996 Aug; 278(2):971-9. PubMed ID: 8768755
[TBL] [Abstract][Full Text] [Related]
25. Preclinical pharmacology of the natural product anticancer agent 10-hydroxycamptothecin, an inhibitor of topoisomerase I.
Zhang R; Li Y; Cai Q; Liu T; Sun H; Chambless B
Cancer Chemother Pharmacol; 1998; 41(4):257-67. PubMed ID: 9488594
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics and metabolism of a novel antifibrotic drug pirfenidone, in mice following intravenous administration.
Giri SN; Wang Q; Xie Y; Lango J; Morin D; Margolin SB; Buckpitt AR
Biopharm Drug Dispos; 2002 Jul; 23(5):203-11. PubMed ID: 12116052
[TBL] [Abstract][Full Text] [Related]
27. The absorption, distribution, metabolism and excretion of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in rats and dogs.
Halpin RA; Geer LA; Zhang KE; Marks TM; Dean DC; Jones AN; Melillo D; Doss G; Vyas KP
Drug Metab Dispos; 2000 Oct; 28(10):1244-54. PubMed ID: 10997947
[TBL] [Abstract][Full Text] [Related]
28. Preclinical pharmacology of the novel antitumor agent adaphostin, a tyrphostin analog that inhibits bcr/abl.
Li M; Wang H; Hill DL; Stinson S; Veley K; Grossi I; Peggins J; Covey JM; Zhang R
Cancer Chemother Pharmacol; 2006 May; 57(5):607-14. PubMed ID: 16331493
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of the new thyrotropin releasing hormone analogue montirelin hydrate. 2nd communication: distribution and transfer into the fetus and milk after a single intravenous administration and pharmacokinetics and enzyme induction after repeated intravenous administration to rats.
Sugimoto T; Hayashi T; Okita A; Morino A
Arzneimittelforschung; 1996 Feb; 46(2):114-27. PubMed ID: 8720299
[TBL] [Abstract][Full Text] [Related]
30. Preclinical pharmacokinetics and bioavailability of noscapine, a tubulin-binding anticancer agent.
Aneja R; Dhiman N; Idnani J; Awasthi A; Arora SK; Chandra R; Joshi HC
Cancer Chemother Pharmacol; 2007 Nov; 60(6):831-9. PubMed ID: 17285314
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics and tissue distribution of cryptophycin 52 (C-52) epoxide and cryptophycin 55 (C-55) chlorohydrin in mice with subcutaneous tumors.
Boinpally RR; Polin L; Zhou SL; Jasti BR; Wiegand RA; White K; Kushner J; Horwitz JP; Corbett TH; Parchment RE
Cancer Chemother Pharmacol; 2003 Jul; 52(1):25-33. PubMed ID: 12739061
[TBL] [Abstract][Full Text] [Related]
32. Metabolism, disposition, excretion, and pharmacokinetics of levormeloxifene, a selective estrogen receptor modulator, in the rat.
Mountfield RJ; Kiehr B; John BA
Drug Metab Dispos; 2000 May; 28(5):503-13. PubMed ID: 10772628
[TBL] [Abstract][Full Text] [Related]
33. High performance liquid chromatographic analysis and preclinical pharmacokinetics of the heteroarotinoid antitumor agent, SHetA2.
Zhang Y; Hua Y; Benbrook DM; Covey JM; Dai G; Liu Z; Chan KK
Cancer Chemother Pharmacol; 2006 Nov; 58(5):561-9. PubMed ID: 16534614
[TBL] [Abstract][Full Text] [Related]
34. Distribution, elimination, and test for carcinogenicity of 2,6-dinitrotoluene after intraperitoneal and oral administration to strain a mice.
Schut HA; Loeb TR; Grimes LA; Stoner GD
J Toxicol Environ Health; 1983; 12(4-6):659-70. PubMed ID: 6668616
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of guanosine in rats following intravenous or intramuscular administration of a 1:1 mixture of guanosine and acriflavine, a potential antitumor agent.
Shin DH; Choi KS; Cho BS; Song S; Moon DC; Hong JT; Lee CK; Chung YB
Arch Pharm Res; 2008 Oct; 31(10):1347-53. PubMed ID: 18958427
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics and bioavailability of diisopropanolamine (DIPA) in rats following intravenous or dermal application.
Saghir SA; Frantz SW; Spence MW; Nolan RJ; Lowe ER; Rick DL; Bartels MJ
Food Chem Toxicol; 2007 Oct; 45(10):2047-56. PubMed ID: 17583405
[TBL] [Abstract][Full Text] [Related]
37. Bryostatin 1 activates splenic lymphocytes and induces sustained depletion of splenocyte protein kinase C activity in vivo after a single intravenous administration.
Bear HD; McFadden AW; Kostuchenko PJ; Lipshy KA; Hamad GG; Turner AJ; Roberts JD; Carr M; Carr S; Grant S
Anticancer Drugs; 1996 May; 7(3):299-306. PubMed ID: 8792004
[TBL] [Abstract][Full Text] [Related]
38. Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1.
Egorin MJ; Zuhowski EG; Rosen DM; Sentz DL; Covey JM; Eiseman JL
Cancer Chemother Pharmacol; 2001 Apr; 47(4):291-302. PubMed ID: 11345645
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetic studies in mice of two new thioxanthenones (183577 and 232759) that showed preferential solid tumor activity.
Foster BJ; Wiegand RA; Pugh S; LoRusso PM; Rake J; Corbett TH
Clin Cancer Res; 1997 Nov; 3(11):2047-53. PubMed ID: 9815596
[TBL] [Abstract][Full Text] [Related]
40. Fate of tritiated didemnin B in mice: excretion and tissue concentrations after an intraperitoneal dose.
Beasley VR; Bruno SJ; Burner JS; Choi BW; Rinehart KL; Koritz GD; Levengood JM
Biopharm Drug Dispos; 2005 Nov; 26(8):341-51. PubMed ID: 16082719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
